Lab Results
What Is an Optimal IGF-1 Level?
Most labs flag IGF-1 as 'normal' across a wide age-adjusted range, but research suggests the sweet spot for longevity and metabolic health is narrower than that. Understanding what your IGF-1 number actually means — and what moves it — can change how you approach recovery, body composition, and healthy aging.

What Is an Optimal IGF-1 Level?
For most healthy adults, an optimal IGF-1 level sits in the upper-middle of the age-adjusted reference range — roughly 150–250 ng/mL for adults aged 30–60 — not simply "within normal limits." The main caveat: optimal IGF-1 is highly context-dependent. Very high levels (above 300 ng/mL in adults) are linked to increased cancer risk in epidemiological data, while very low levels (below 100 ng/mL) associate with poor muscle maintenance, metabolic dysfunction, and cardiovascular risk. Athletes, people recovering from illness, and older adults each have different targets.
---
What Does IGF-1 Actually Do?
Insulin-like growth factor 1 (IGF-1) is a peptide hormone produced primarily in the liver in response to growth hormone (GH) signaling. It mediates most of GH's anabolic effects — stimulating cell growth, protein synthesis, and tissue repair across nearly every organ system.
Beyond muscle, IGF-1 plays a central role in:
- Bone density: IGF-1 activates osteoblasts and is a key driver of peak bone mass in adolescence and maintenance in adulthood (Boonen et al., JCEM 1999; PMID: 10022403).
- Cognitive function: IGF-1 receptors are dense in the hippocampus and prefrontal cortex; low levels correlate with accelerated cognitive decline in aging populations.
- Insulin sensitivity: IGF-1 shares structural similarity with insulin and exerts modest insulin-like metabolic effects, reducing fasting glucose and improving glucose uptake in skeletal muscle.
- Cellular repair and autophagy: Here is where the nuance begins. IGF-1 signaling via the PI3K/Akt/mTOR pathway suppresses autophagy — the cellular self-cleaning process associated with longevity. This is why some longevity researchers view chronically elevated IGF-1 as a double-edged sword.
Understanding this dual role — anabolic and growth-promoting on one hand, potentially pro-aging on the other — is essential to interpreting your personal number. As with many biomarkers, context and trajectory matter more than a single snapshot. For comparison, reviewing how standard lab reference ranges differ from optimal ranges provides useful framing.
---
IGF-1 Reference Ranges vs. Optimal Ranges
Most clinical laboratories report IGF-1 using broad, age-adjusted reference intervals. Here's what those ranges typically look like, alongside narrower "functional optimal" zones supported by the research literature:
| Age Group | Typical Lab Reference Range (ng/mL) | Functional Optimal (ng/mL) | Notes |
|---|---|---|---|
| 20–30 | 115–355 | 200–300 | Peak anabolic years; higher end acceptable |
| 31–45 | 100–310 | 170–260 | Gradual decline expected; aim for upper-middle |
| 46–60 | 85–275 | 150–240 | Below 120 warrants investigation |
| 61–75 | 75–235 | 120–200 | Low end links to sarcopenia risk |
| 75+ | 60–190 | 100–170 | Quality of life and functional outcomes prioritized |
These "functional optimal" zones are derived from population studies linking mid-to-upper-normal IGF-1 to lower all-cause mortality (Renehan et al., Lancet 2004; PMID: 15016485), better musculoskeletal function, and favorable metabolic profiles — without the cancer-associated signal seen at the high extreme.
Lab ranges alone can be misleading. Someone at 90 ng/mL might be flagged "normal" for their age bracket but still experience low IGF-1 symptoms like fatigue, poor recovery, and declining lean mass. As with optimal fasting insulin levels, the reference range is a population floor, not a performance ceiling.
---
What Causes IGF-1 to Go Out of Range?
If you've received an unexpected result, the causes of IGF-1 being out of range are worth reviewing in detail. For this article, here is a structured summary:
Low IGF-1 (below functional optimal) is associated with:
- Growth hormone deficiency (pituitary dysfunction)
- Liver disease or reduced hepatic IGF-1 synthesis capacity
- Protein malnutrition or very low-calorie dieting
- Chronic systemic inflammation (CRP elevation suppresses GH signaling)
- Hypothyroidism — thyroid hormone is required for GH receptor expression
- Aging-related somatopause (physiological GH decline after age 30)
- Insulin resistance paradox: some individuals with hyperinsulinemia show low IGF-1 despite high GH, due to hepatic GH resistance
High IGF-1 (above functional optimal or above lab upper limit) is associated with:
- Acromegaly (pathological GH excess from a pituitary adenoma)
- Exogenous GH administration
- High protein intake combined with significant resistance training
- Certain cancers (some tumors produce IGF-1 locally)
- Obesity paradox: central adiposity can transiently raise IGF-1 through insulin-driven GH secretion
Chronic inflammation is a consistent thread running through low-IGF-1 presentations. Elevated CRP and interleukin-6 impair GH receptor sensitivity in the liver, suppressing IGF-1 output even when GH pulses are adequate. This is one reason optimal CRP levels are worth monitoring alongside IGF-1.
---
IGF-1 and Longevity: The Paradox
The longevity data on IGF-1 is genuinely complex, and you'll encounter conflicting claims in the supplement and biohacking space. Here's an honest summary.
Lower IGF-1 in animal models: In C. elegans, Drosophila, and rodents, reduced insulin/IGF-1 signaling (IIS pathway) consistently extends lifespan — sometimes dramatically. Caloric restriction lowers IGF-1 and extends rodent lifespan. These findings sparked hypotheses that lower IGF-1 is better for human longevity too.
Human epidemiology tells a more nuanced story: A large meta-analysis of prospective studies found that IGF-1 follows a U-shaped association with mortality in humans. Both the lowest quartile (below ~100 ng/mL) and the highest quartile (above ~300 ng/mL in older adults) are associated with higher all-cause mortality compared to the middle (Burgers et al., Journal of Clinical Endocrinology & Metabolism 2011; PMID: 21715540).
Cancer epidemiology: Elevated circulating IGF-1 is associated with modestly increased risk of premenopausal breast cancer, colorectal cancer, and prostate cancer in large cohort data (Key et al., Lancet Oncology 2010; PMID: 20493771). However, the absolute risk increase is small at levels within the upper-normal lab range — most of the signal comes from pathological elevations.
The practical takeaway: For healthy adults, the goal is not to minimize IGF-1, but to maintain it in the functional optimal band. Chasing very low IGF-1 through aggressive caloric restriction trades muscle mass, bone density, and cognitive function for a longevity hypothesis that is not robustly established in humans.
---
IGF-1 Replacement Therapy
IGF-1 replacement therapy — using recombinant human IGF-1 (mecasermin, sold as Increlex) — is an FDA-approved treatment for children with severe primary IGF-1 deficiency (Laron syndrome) due to GH receptor insensitivity. Its use in adults is more limited and largely investigational or off-label.
Approved and evidence-backed uses:
- Severe IGF-1 deficiency in children: mecasermin at 0.04–0.12 mg/kg/dose twice daily has demonstrated significant improvements in height velocity and metabolic markers (Chernausek et al., JCEM 2007; PMID: 17405840).
- ALS (amyotrophic lateral sclerosis): early trials showed modest benefit in slowing functional decline; subsequent larger trials produced mixed results.
- Insulin resistance in patients with leprechaunism and Rabson-Mendenhall syndrome: IGF-1 replacement has demonstrated glucose-lowering effects in these rare conditions.
What about adults with low-normal IGF-1?
This is where most people's questions arise. Direct IGF-1 therapy for "age-related" low levels is not standard of care and carries significant risks: hypoglycemia (IGF-1 lowers blood sugar), fluid retention, jaw/hand growth, and theoretical cancer promotion with long-term use.
Most clinicians working in functional and longevity medicine address low-normal IGF-1 by targeting upstream drivers: optimizing GH pulse amplitude through sleep quality, resistance training, adequate dietary protein, and treating any underlying thyroid or inflammatory conditions — rather than administering IGF-1 or GH directly.
---
Natural Strategies That Influence IGF-1
Several lifestyle and nutritional variables have demonstrated meaningful effects on circulating IGF-1 in controlled trials:
1. Resistance training: Progressive resistance exercise acutely raises GH, which drives IGF-1 synthesis. A 16-week resistance training program in older adults raised IGF-1 by approximately 20% compared to sedentary controls.
2. Dietary protein: IGF-1 is exquisitely sensitive to protein intake. Vegan diets typically produce 13% lower IGF-1 than omnivore diets in cohort data, largely due to lower protein and leucine availability. Adequate intake (1.2–1.6 g/kg/day) supports hepatic IGF-1 output.
3. Sleep quality: The majority of GH secretion occurs during slow-wave sleep (SWS). Poor sleep — fewer than 6 hours or fragmented sleep architecture — measurably blunts GH pulsatility and downstream IGF-1.
4. Zinc adequacy: Zinc is a cofactor for GH receptor signaling. Zinc deficiency suppresses both GH and IGF-1 — a well-characterized relationship in pediatric nutrition literature (Hambidge, AJCN 2000; PMID: 10919955). Repleting zinc in deficient adults can modestly raise IGF-1 within weeks.
5. Managing chronic inflammation: As noted above, elevated CRP and IL-6 blunt hepatic GH receptor expression. Reducing inflammatory load — through omega-3 fatty acids, anti-inflammatory diet patterns, and addressing root causes — can improve GH sensitivity and support IGF-1 recovery.
---
What This Means for Your Formula
Ones analyzes biomarkers including IGF-1, alongside inflammatory markers like CRP, thyroid function, and metabolic indicators, to identify the upstream drivers most likely suppressing or elevating your levels. The platform then builds a personalized capsule formula targeting those mechanisms — not IGF-1 directly, but the physiological environment that governs it.
For individuals presenting with low-normal IGF-1 alongside elevated inflammatory markers and suboptimal zinc status, a Ones formula might include:
- Zinc (as zinc bisglycinate, 15–25 mg): Supporting GH receptor signaling and IGF-1 synthesis. The dose aligns with the repletion range used in deficiency correction trials, not arbitrary supplementation.
- Omega-3 (EPA/DHA at clinical doses): EPA and DHA reduce IL-6 and TNF-α, addressing the inflammatory suppression of hepatic GH sensitivity. Ones sources pharmaceutical-grade EPA/DHA dosed to the ranges used in intervention trials.
- Liver Support (Ones proprietary System Blend): The liver is the primary site of IGF-1 synthesis. Ones' Liver Support blend is formulated to support hepatic function and reduce oxidative stress in hepatocytes — relevant when low IGF-1 traces back to reduced hepatic output rather than GH deficiency.
If your IGF-1 is running high alongside other metabolic signals, the formula emphasis shifts entirely — toward inflammation resolution, blood sugar regulation, and ingredients that support insulin sensitivity rather than those that might further stimulate anabolic signaling.
This is the core difference between a personalized formula and a generic stack: the same biomarker reading doesn't always call for the same response.
---
Key Takeaways
- "Normal" and "optimal" IGF-1 are not the same thing. A result within the lab reference range can still be functionally low, particularly for adults in the lower quartile of their age bracket.
- The functional optimal for most adults is roughly 150–250 ng/mL, sitting in the upper-middle of age-adjusted ranges — high enough to support muscle, bone, and cognition, without reaching the elevated zone linked to cancer epidemiology.
- IGF-1 follows a U-shaped mortality curve in humans. Both very low and very high levels are associated with worse outcomes; the longevity goal is optimization, not minimization.
- Low IGF-1 most commonly traces back to poor sleep, protein insufficiency, chronic inflammation, zinc inadequacy, or thyroid dysfunction — all of which are modifiable.
- IGF-1 replacement therapy (mecasermin) is FDA-approved only for severe deficiency in children; adult off-label use carries meaningful risks and is not standard of care.
- Upstream interventions — sleep quality, resistance training, protein intake, anti-inflammatory nutrition, and correcting micronutrient gaps — are the first-line approach to supporting healthy IGF-1 in adults without pathological GH deficiency.
---
Always consult a qualified healthcare provider before making changes to your supplement regimen or interpreting lab results for clinical decisions. IGF-1 results should be interpreted in the context of your full clinical picture, including GH stimulation testing where indicated.